Applications of 2-Bromoethylamine Hydrobromide in Industrial Manufacturing

As an industrial-grade manufacturer, we supply 2-Bromoethylamine Hydrobromide to specialized downstream sectors that value high purity and reliable batch consistency. Its unique reactivity profile positions it as a key intermediate in multiple high-value chemical synthesis lanes, supporting advanced materials, pharmaceuticals, and life sciences reagents. The following sections detail core application scenarios compliant with global standards and industrial practices.

1. Pharmaceutical Active Ingredient Synthesis

2-Bromoethylamine Hydrobromide serves as a strategic intermediate for active pharmaceutical ingredient (API) synthesis, specifically in the production of alkylamine-based drug molecules. Pharmaceutical manufacturers introduce it during nucleophilic substitution steps to incorporate ethylamine chains into API frameworks such as antihypertensive agents and neuroactive medications. Key stages include salt exchange, isolation of the intermediate, and controlled downstream coupling. Attention to GMP and batch traceability is critical from kilo lab through commercial scale, ensuring direct compliance with international regulatory frameworks.

Industry compliance standards

• USP (United States Pharmacopeia)
• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU-GMP (European Union Good Manufacturing Practice)
• FDA 21 CFR Part 211

Typical usage ratio

• Ranges from 0.15 to 0.65 molar equivalents depending on target molecule and excess needed to drive the reaction to completion. Adjusted based on yield optimization and impurities profile.

Downstream process integration

• Charged in acylation or amination steps using controlled addition protocols. Reaction conducted in closed reactors under temperature-monitored conditions. Quenching and extraction routes selected according to API synthesis path.

Final product types

• API intermediates for antihypertensive drugs (e.g., betaxolol base)
• Neuroactive pharmaceutical molecules
• Beta-blocker synthesis intermediates
• Chemically defined research compounds for clinical trial use

2. Agrochemical Intermediate Manufacturing

Agrochemical producers employ 2-Bromoethylamine Hydrobromide to construct key intermediate structures required for the synthesis of select herbicides and fungicides. The compound is introduced as an alkylating agent, enabling functionalization of aromatic backbones typical in crop protection molecules. Process engineers set dosing levels based on targeted molecular transformations, with careful monitoring to prevent over-alkylation and by-product formation. Application adheres to stringent quality controls to avoid batch contamination and safeguard end-use compliance.

Industry compliance standards

• FAO/WHO Technical Specifications for Plant Protection Products
• REACH (EC 1907/2006) Registration for intermediates
• ISO 9001:2015 Quality Management for chemical manufacturing
• Chinese GB/T 19001-2016 Quality System for agrochemical production

Typical usage ratio

• Usually 1.0 to 1.3 molar equivalents relative to the nucleophile substrate, tuned to safeguard conversion efficiency in scale-up scenarios.

Downstream process integration

• Added in jacketed reactor vessels, often as an aqueous or alcohol solution. Alkylation/reduction steps followed by controlled washing and phase separation before downstream purification or crystallization of target intermediates.

Final product types

• Pyridine-based herbicide intermediates (e.g., for Picloram synthesis)
• Phenoxyacetic acid fungicide intermediates
• Nitrogenous crop protection compounds
• Specialty agrochemical building blocks

3. Pharmaceutical Impurity Standards Production

Contract reference standard producers use 2-Bromoethylamine Hydrobromide to manufacture well-defined impurity markers for regulatory compliance, stability studies, and analytical release testing. Laboratories synthesize these markers by introducing ethylamine moieties into specified parent structures under documented, reproducible conditions. End-to-end record-keeping, material certification, and traceable batch handling are non-negotiable, as these standards underpin reference method verification and regulatory submissions for finished pharmaceutical products worldwide.

Industry compliance standards

• USP Reference Standards SOPs
• EP (European Pharmacopoeia) reference impurity guidelines
• ISO/IEC 17025 for analytical reference material production
• FDA cGMP for reference drug standards

Typical usage ratio

• Generally 0.10 to 0.40 molar equivalents based on specific impurity structure and analytical batch size, with excess used to ensure marker formation without retesting cycles.

Downstream process integration

• Employed during semi-preparative HPLC marker synthesis or batch synthesis in dedicated reference material lines, followed by purification and full analytical characterization per pharmacopoeial requirements.

Final product types

• Certified pharmaceutical impurity markers
• USP/EP-listed reference substances
• Calibrants for drug release testing
• Analytical grade impurity standards

4. Biological Reagent and Linker Synthesis

Life sciences reagent manufacturers rely on 2-Bromoethylamine Hydrobromide as a source for bi-functional linker assembly, particularly for conjugating proteins, peptides, and oligonucleotides. The compound’s primary amine group makes it suitable for coupling to activated carboxylates or other reactive groups under aqueous or mixed solvent systems. Downstream processes demand high-purity inputs and validated batch records to support bioconjugation for diagnostics and custom reagent kit manufacturing. Material traceability and low-level contaminant screening remain mandatory.

Industry compliance standards

• ISO 13485 (Medical Device and IVD Quality Management)
• ANSI/NSF 173 Section 7.2 Purity Standards for Reagents
• OECD Principles of Good Laboratory Practice (GLP)
• ISO 9001 for research reagent manufacturing

Typical usage ratio

• Typically 0.05 to 0.30 molar equivalents as a controlled reactant in multi-functional linker assembly, with addition rates optimized during process development to maintain high labeling efficiency.

Downstream process integration

• Introduced as a pre-activated solution under nitrogen or argon, reacted with target biomolecule in batch or flow systems. Purified by dialysis or column chromatography to isolate functionalized linkers.

Final product types

• Protein crosslinker derivatives
• Fluorescent labeling kit components
• Antibody-drug conjugate precursors
• Custom DNA/RNA linker molecules